钙卫蛋白检测市场
钙卫蛋白检测市场：2026年市场规模约为6.4亿美元，2031年市场规模约为12.3亿美元；预测期复合年增长率为13.72%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 95.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
待补内容：缺少细分份额核心结论
钙卫蛋白检测市场：2026年市场规模约为6.4亿美元，2031年市场规模约为12.3亿美元；预测期复合年增长率为13.72%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 13.72% | 机构预测 |
| 市场规模 | 2026 | USD 0.64 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.23 billion | 机构预测 |
主要参与者
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Inflammatory Bowel Disease Prevalence | +3.800% | Global, concentrated in North America, Europe, and rapidly urbanizing APAC | Long term (≥ 4 years) |
| Guideline-Based IBD and IBS Differentiation | +2.200% | North America and Europe, with early spillover to APAC and South America | Medium term (2-4 years) |
| Demand for Non-Invasive Disease Monitoring | +2.500% | Global, with strongest demand in Europe and North America | Long term (≥ 4 years) |
| Expansion of Automated High-Throughput Testing | +1.800% | North America, Europe, and APAC core markets | Medium term (2-4 years) |
| Point-of-Care and Home-Based Monitoring Adoption | +1.300% | Europe, North America, and early-adoption APAC markets | Medium term (2-4 years) |
| Interoperable Longitudinal Monitoring Through Digital Connectivity | +0.900% | National systems, with early gains in UK NHS trusts and major U.S. health systems | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Limited Cross-Assay Standardization | -0.800% | Global, most acute in multisite health systems in Europe and North America | Long term (≥ 4 years) |
| Variable Reimbursement and Testing Accessibility | -0.900% | North America and emerging APAC reimbursement systems | Medium term (2-4 years) |
| Stool Collection and Patient Compliance Friction | -0.500% | Global, with higher noncompliance in primary care | Short term (≤ 2 years) |
| Endoscopy-Centered Hospital Economics Delaying Biomarker-First Pathways | -0.600% | North America and select European markets | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for calprotectin testing?
Rising IBD prevalence, guideline-led triage, and repeat monitoring for biologic therapy are increasing testing demand.
What is the forecast growth rate for calprotectin testing through 2031?
The sector is projected to grow at a 13.7% CAGR from 2026 to 2031, reaching USD 1,233.3 million.
Which assay format is growing fastest?
CLIA and other automated assays are projected to grow at a 13.9% CAGR through 2031.
Why is fecal calprotectin used in IBD care?
It helps distinguish inflammatory from noninflammatory disease and supports monitoring without routine endoscopy.
Which region is growing fastest for calprotectin testing?
Asia Pacific is projected to grow at a 14.5% CAGR through 2031.
What limits wider adoption of calprotectin testing?
Cross-assay variation, uneven reimbursement, stool collection friction, and endoscopy-centered care models remain constraints.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence